ClinicalTrials.gg
CompletedNCT05553470Updated Mar 30, 2025

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

A Phase 1 interventional study of Miricorilant in Non-alcoholic Steatohepatitis (NASH), sponsored by Corcept Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Mar 2022, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
376th of 460
19 · median 56
Started
2022
with 37 others
Phase 1
79 of 547
6 open now
Registered
460th of 547
by date
Lead sponsor
8 of 547
Corcept Therapeutics

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 376th largest by enrollment of the 460 interventional ones that give a count, is one of 38 that started in 2022, is one of 79 in phase 1, and was the 460th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH).

Read the detailed description

A reduced, adaptive study design will be used to compare the PK of miricorilant between participants with normal hepatic function and participants with hepatic impairment according to the Child-Pugh (CP) classification. Initially, participants with moderate hepatic impairment will be enrolled. Since indications for the development of miricorilant include participants with NASH, 3 or 4 of these participants will have NASH. Healthy control participants will be selected matched to these participants with moderate hepatic impairment according to gender, age (± 10 years), and weight (± 20 %) using a mean matching procedure. Based on the observed effect of moderate hepatic impairment on the miricorilant PK profile following an interim PK analysis, an optional group of participants with mild hepatic impairment may be evaluated. This optional group, matched to the participants with moderate hepatic impairment using the same procedure, will be enrolled to evaluate the effect of mild hepatic impairment on miricorilant PK.

03

Conditions studied

  • Non-alcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoker or light smokers (no more than 5 cigarettes/day or nicotine equivalent) with ≥18.0 and ≤32 kg/m2 and body weight ≥50.0 kg.
  • Female participants must be non-childbearing or willing to use an acceptable intra-uterine device 4 weeks prior and throughout the study and for 90 days after study drug administration.
  • Male participants who are sexually active must be willing to use an acceptable contraceptive method from dosing until at least 90 days after study drug administration.
  • Total abstinence from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant.
  • Male participants must be willing to not donate sperm until 90 days following the administration of the study drug.
  • Estimated (eGFR) ≥ 60 mL/min/1.73 m\^2 at screening, by the Modification of Diet in Renal Disease, 4 variable (MDRD4) Equation.

Additional Inclusion Criteria for Control Group Participants Only:

  • On a population basis, matched to participants with moderate hepatic impairment according to gender, age (± 10 years), and weight (± 20 %).
  • Absence of history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease.
  • Non-clinically significant deviation for laboratory tests results (albumin ≥ the lower limit of normal (LLN), total ≤ , (AST) ≤ upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ ULN, alkaline phosphatase ≤ ULN).

Additional Inclusion Criteria for Participants With Hepatic Impairment Only:

  • Participant with stable hepatic impairment ( [CP] class A or B according to group)
  • Documented parenchymal hepatic disease as evidenced by ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), or .
  • Participants who have chronic (≥ 6 months) mild or moderate hepatic impairment that has been clinically stable
  • Have hepatic impairment as assessed by a CP classification score: Mild (5-6 points), or Moderate (7-9 points) impaired hepatic function with known medical history of liver disease.
  • Have non-clinically significant findings at physical examination and in clinically laboratory evaluations.
  • Moderate hepatic impairment participants with nonalcoholic steatohepatitis (NASH) only should have a history or presence of metabolic syndrome or type 2 diabetes, clinical characteristics or prior liver biopsy, ALT ≥ 43 IU/L for men and ≥ 28 IU/L for women, and except for participants with prior liver biopsy, participants should have currently or previously one of the following: MRI-iron-corrected T1 (cT1) value > 800 ms, MRI proton density fat fraction (PDFF) liver fat content ≥ 8 % or FibroScan liver stiffness measurement (LSM) ≥ 8.5 kilopascals (kPa).

Exclusion criteria

Exclusion Criteria:

  • illness or surgery within 4 weeks prior to dosing.
  • Gastrointestinal surgery that interferes with physiological absorption and motility or gastric bands.
  • Clinically significant history or presence of any gastrointestinal pathology, or unresolved gastrointestinal symptoms that can interfere with drug absorption.
  • History of suicidal tendency, disposition to seizures, state of confusion, or clinically relevant psychiatric diseases.
  • Any medical condition that could be aggravated by antagonism, and/or mineralocorticoid antagonism, such as disease, rheumatic disease, hypotension, or postural hypotension.
  • Clinically significant (ECG) abnormalities or vital sign abnormalities at screening
  • Acute viral hepatitis in the 6 calendar months before the administration of the study drug.
  • Positive to Coronavirus disease 2019 (COVID-19) test at screening
  • History of Gilbert's syndrome
  • Uncontrolled hyperlipidemia
  • History of significant drug abuse within 1 year prior to screening or recreational use of soft drugs within 1 month or hard drugs within 3 months prior to screening, unless for hepatic impaired participants only, the participants uses any of these drugs as prescriptions.
  • History of significant alcohol abuse within six months prior to screening or regular use of alcohol within six months prior to the screening visit.
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
  • Female participants with a positive pregnancy test.
  • Participant with a positive alcohol test at screening.
  • History of allergic reactions to miricorilant or other related drugs
  • Known clinically significant to any of the ingredients or of the study drug
  • Previous participation in a study with miricorilant administration.
  • Participated in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to dosing.
  • Participants who have taken oral, parenteral, depot or intra-articular glucocorticoids within 12 months prior to study drug administration; or intranasal, topical, or inhaled glucocorticoids within 2 weeks prior to study drug administration.
  • Male participants (including men who have had vasectomies) with a pregnant or lactating partner.
  • Breast-feeding female participants
  • Inability or difficulty to swallow tablets
  • Inability to be venipunctured and/or tolerate catheter venous access.

Additional Exclusion Criteria for Healthy Group (No Hepatic Impairment) Participants Only:

  • Previously documented parenchymal hepatic disease evidenced by, for example, ultrasonography, computed tomography, magnetic resonance imaging, or .
  • Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for , , or at screening;
  • Participants using medication other than topical products without significant systemic absorption.
  • Participants with a positive urine drug screen at screening.

Additional Exclusion Criteria for Participants with Hepatic Impairment Only:

  • Clinically significant unstable medical conditions or clinically significant acute exacerbation of hepatic disease within 30 days of study drug administration
  • Clinically significant abnormalities of laboratory, ECG, or clinical data that would preclude participation in the study
  • Presence of chronic kidney disease (CKD).
  • Presence of hepatocellular carcinoma or acute hepatic disease from infection or drug toxicity
  • Presence of clinically significant history of lactic acidosis and severe hepatomegaly with steatosis
  • Presence of active stage 2, 3 or stage 4 hepatic encephalopathy
  • Evidence of severe ascites
  • Type 1 or uncontrolled Type 2 diabetes
  • Presence of surgically-created or transjugular intrahepatic portal systemic shunts.
  • Positive test for HIV
  • Positive drug screen at screening
  • Use of prohibited concomitant medication
  • History or clinical evidence of hepatic decompensation or other severe liver impairment.
  • History of liver transplant, or current placement on a liver transplant list.
  • For moderate hepatic impairment participants with NASH, a history or clinical evidence of chronic liver diseases other than nonalcoholic fatty liver disease (NAFLD).
  • Weight loss of > 5% total body weight within 3 months prior to screening.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    No Hepatic Impairment

    Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.

    Drug: Miricorilant

  • Experimental
    Moderate Hepatic Impairment

    Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.

    Drug: Miricorilant

  • Experimental
    Mild Hepatic Impairment

    Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.

    Drug: Miricorilant

Interventions

  • 600 mg miricorilant

    Also known as: CORT118335

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-Time Curve (AUC) from Time Zero to the Last Non-Zero Concentration (AUC 0-t)

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours post-dose

  2. AUC from Time Zero to Infinity (AUC0-∞)

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours post-dose

Secondary outcomes

  1. Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 7

  2. Number of Participants with One or More Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after study drug administration

  3. Number of Participants with Clinically-Significant Vital Sign Abnormality

    Time frame: Day -1, pre-dose and ~ 1, 2, 4, and 24 hours post-dose.

  4. Number of Participants with Clinically-Significant 12-Lead Electrocardiogram (ECG) Abnormality

    Time frame: Day -1, pre-dose and ~1, 2, 4, and 24 hours post-dose, and up to ~Day 7

  5. Number of Participants with Clinically-Significant Laboratory Test Abnormality

    Time frame: Day -1 and up to ~Day 7

07

Study locations

3 sites
  • Site 03
    Rialto, California 92377, United States
  • Site 02
    Miami Lakes, Florida 33104, United States
  • Site 01
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2024, 30 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 30 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Mar 3, 2022
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 13, 2024
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05553470
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Mar 3, 2022
Primary completion
Sep 13, 2024
Completion
Sep 13, 2024
Last update
Mar 30, 2025

Study contacts

Joseph Custodio, PhD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion